KYMR vs. REGN: Kymera Therapeutics vs. Regeneron Pharmaceuticals Stock Comparison

Company Profile

Kymera Therapeutics (KYMR) and Regeneron Pharmaceuticals (REGN) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Regeneron Pharmaceuticals (REGN) has more than two decades of public-market history since April 2, 1991, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Kymera Therapeutics (KYMR) has an aggressive beta of 2.00, indicating higher sensitivity to broad-market moves, while Regeneron Pharmaceuticals (REGN) is defensive at 0.10 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Regeneron Pharmaceuticals (REGN) reports 14.95%, ranking against industry peers normally.

Regeneron Pharmaceuticals (REGN) at 28.51% converts revenue to bottom-line profit above its industry’s benchmark range, while Kymera Therapeutics (KYMR) at 0.00% keeps roughly the typical share for its industry.

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Regeneron Pharmaceuticals (REGN) reports 40.46%, ranking against industry peers normally.

Profitability Metrics

Growth

Regeneron Pharmaceuticals (REGN) at 0.99% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Regeneron Pharmaceuticals (REGN) reports EPS growth of 8.19%, ranked against its industry; Kymera Therapeutics (KYMR) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Kymera Therapeutics (KYMR) at 11.13 and Regeneron Pharmaceuticals (REGN) at 3.35 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Both Kymera Therapeutics (KYMR) at 0.05 and Regeneron Pharmaceuticals (REGN) at 0.08 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Kymera Therapeutics (KYMR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a yield of 0.41%, ranking against industry peers normally.

Kymera Therapeutics (KYMR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a payout of 8.18%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Regeneron Pharmaceuticals (REGN) trades at 19.99 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

Regeneron Pharmaceuticals (REGN) at 5.54 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.

Regeneron Pharmaceuticals (REGN) at 2.71 is valued about in line with its industry on P/B ratio, while Kymera Therapeutics (KYMR) at 6.96 carries an above-peer premium to book — KYMR is pricier on assets.

Valuation Metrics